In patients with the condition, known as left bundle branch block or LBBB, CRT-D therapy reduced heart failure progression and the risk of ventricular tachyarrhythmias, fast and potentially life-threatening heart rhythms. Heart failure patients without LBBB did not receive any benefit from the therapy.
The analysis, based on the major study which tested the device – the MADIT-CRT trial – led the FDA to extend the approval of the CRT-D in September 2010 to patients with mild heart failure and LBBB to prevent progression to advanced heart failure. The device, developed by Boston Scientific, was originally approved to treat patients with severe heart failure.
Cardiac resynchronization therapy with defibrillator (CRT–D)“This study allowed us to identify the specific set of patients that receive the greatest benefit from this device,” said Wojciech Zareba, M.D., Ph.D., lead study author and director of the Heart Research Follow-up Program at the University of Rochester Medical Center. “Our analysis highlights the fact that this therapy is not equally effective in all mild heart failure patients and was the basis of the FDA’s approval of the therapy only in patients with left bundle branch block.”
Zareba’s team found that patients with LBBB who received CRT-D therapy had a significant 53 percent reduction in the risk of a heart failure event, such as being hospitalized with heart failure symptoms, or death, compared to LBBB patients who only received an implantable cardioverter defibrillator (ICD). The risk of ventricular tachyarrhythmias was also considerably less in LBBB patients with CRT-D.
Arthur J. Moss, M.D.CRT-D therapy combines an ICD, which senses dangerous abnormal heart rhythms and attempts to shock the heart back into a normal rhythm, with cardiac resynchronization therapy (CRT), which coordinates the beating of the heart so it can pump blood throughout the body more effectively.
The study included 1,817 patients and researchers analyzed electrocardiograms – maps of the heart’s electrical activity – to determine which patients had electrical disturbances and what type. Seventy percent of study participants had LBBB. LBBB patients were more often female and had higher rates of non-ischemic heart disease, a disorder typically characterized by inflammatory scarring of the heart muscle.
Study authors evaluated the effects of CRT-D versus ICD therapy in patients with and without LBBB. They found that in LBBB patients, CRT-D therapy effectively prevented deterioration of the heart, otherwise known as cardiac remodeling, by preventing enlargement of the heart with more effective contraction of the heart.
“We believe this therapy is so effective in patients with LBBB because their hearts don’t contract in a synchronous way, rather, the pumping action is quite out of sync,” noted Zareba. “CRT-D therapy paces the heart and makes these patients much better very quickly.”
Beyond mild heart failure patients, the results are leading experts to rethink current guidelines recommending the use of CRT-D therapy for all advanced heart failure patients. In this age of personalized medicine, as treatments are continually directed towards subsets of patients with particular characteristics or biologic markers, the group of advanced heart failure patients that receive CRT-D therapy may be narrowed to those with LBBB, as well.
The MADIT-CRT trial, led by Arthur J. Moss, M.D., cardiologist at the University of Rochester Medical Center, was supported by a research grant from Boston Scientific to the University of Rochester. The sub-analysis, led by Zareba, was also sponsored by Boston Scientific.For Media Inquiries:
Emily Boynton | EurekAlert!
A better way to measure the stiffness of cancer cells
01.03.2017 | Duke University
Humans have three times more brown body fat
01.03.2017 | Technische Universität München
Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to simulate these confined natural conditions in artificial vesicles for the first time. As reported in the academic journal Small, the results are offering better insight into the development of nanoreactors and artificial organelles.
Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to...
On January 15, 2009, Chesley B. Sullenberger was celebrated world-wide: after the two engines had failed due to bird strike, he and his flight crew succeeded after a glide flight with an Airbus A320 in ditching on the Hudson River. All 155 people on board were saved.
On January 15, 2009, Chesley B. Sullenberger was celebrated world-wide: after the two engines had failed due to bird strike, he and his flight crew succeeded...
Cells need to repair damaged DNA in our genes to prevent the development of cancer and other diseases. Our cells therefore activate and send “repair-proteins”...
The Fraunhofer IWS Dresden and Technische Universität Dresden inaugurated their jointly operated Center for Additive Manufacturing Dresden (AMCD) with a festive ceremony on February 7, 2017. Scientists from various disciplines perform research on materials, additive manufacturing processes and innovative technologies, which build up components in a layer by layer process. This technology opens up new horizons for component design and combinations of functions. For example during fabrication, electrical conductors and sensors are already able to be additively manufactured into components. They provide information about stress conditions of a product during operation.
The 3D-printing technology, or additive manufacturing as it is often called, has long made the step out of scientific research laboratories into industrial...
13.02.2017 | Event News
10.02.2017 | Event News
09.02.2017 | Event News
01.03.2017 | Health and Medicine
01.03.2017 | Physics and Astronomy
01.03.2017 | Life Sciences